Semi-Annual Consolidated Statement Of Comprehensive Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7577431

Concept 2022-04-01 to
2022-12-31
2021-04-01 to
2021-12-31
Semi-annual consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
4,183,000,000 JPY
4,082,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
858,000,000 JPY
61,000,000 JPY
Remeasurements of defined benefit plans, net of tax
20,000,000 JPY
22,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
477,000,000 JPY
89,000,000 JPY
Other comprehensive income
1,355,000,000 JPY
173,000,000 JPY
Comprehensive income
5,538,000,000 JPY
4,256,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
5,538,000,000 JPY
4,256,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.